Metraipolis › archive › dc_725ce299f6fb
Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study — Europe PMC PMID:41156158
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41156158
- DOI
- 10.3390/jcm14207287
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T07:23:39.846Z
- SHA-256 of the archived text
661550b64dd22397cc9be689c2ab72119ba90978138757dbb01fade215993e42- Stable URL of this page
https://metraipolis.com/documento/dc_725ce299f6fb
How to cite
Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study — Europe PMC PMID:41156158 — Europe PMC (en), https://europepmc.org/article/MED/41156158 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_725ce299f6fb (Metraipolis archive dc_725ce299f6fb, sha256 661550b64dd22397cc9be689c2ab72119ba90978138757dbb01fade215993e42)
BibTeX
@misc{dc725ce299f6fb,
title = {Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study — Europe PMC PMID:41156158},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41156158},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_725ce299f6fb; sha256 661550b64dd22397cc9be689c2ab72119ba90978138757dbb01fade215993e42},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41156158. Agents can read the archived copy with the MCP tool read_document.